Latigo Biotherapeutics Inc. (LTGO)
NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LTGO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $861.89M
- EPS (TTM)
- -$6.07
- Dividend yield
- None
- 52-week range
- 10.24 – 25.93
- Day range
- 11.91 – 13.35
- Volume / Avg
- 267.17K / 309.60K
- Beta
- —
- Shares outstanding
- 66.30M
- Next earnings
- Dec 3, 2026
52-week range
LTGO stock today
On Nov 20, LTGO ended the session at $13.00, shedding $0.24 (1.81%), versus the S&P 500's 3.70% decline. At this level, LTGO sits near the bottom of its 52-week range of $10.24 to $25.93: 49.9% below the high, set on Aug 27, 2026 and 27.0% above the low. Latigo Biotherapeutics has posted a net loss over the last twelve months (EPS of -$6.07), so its P/E ratio is not meaningful.
The company is scheduled to report Sep/2026 results on Dec 3.
Summary generated from market data by MetaCap's automated system. Methodology
About Latigo Biotherapeutics
Company profileLatigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Todd N. Smith
- Headquarters
- Thousand Oaks, CA
- Employees
- 66
- IPO year
- 2026
- Website
- latigobio.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$52.25+301.92%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 3, 2026
- Last reported (Sep/2026)
- Dec 3, 2026
- EPS actual vs est.
- $-0.55 vs —
LTGO news
All LTGO newsLatigo Biotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MTRIMentari Therapeutics Inc. | 14.70 | -3.57% | $856.94M | vs LTGO |
| AKTSAktis Oncology Inc. | 16.15 | -1.52% | $901.14M | vs LTGO |
| PHARPharming Group N.V. ADS | 11.54 | -5.10% | $816.78M | vs LTGO |
| SVRASavara Inc. | 4.26 | -18.23% | $939.86M | vs LTGO |
| CRVSCorvus Pharmaceuticals Inc. | 9.67 | -3.40% | $815.69M | vs LTGO |
| MLTXMoonLake Immunotherapeutics Class A | 11.07 | +0.36% | $942.13M | vs LTGO |
| VSTMVerastem Inc. | 6.33 | -7.73% | $797.67M | vs LTGO |
| CYRXCryoPort Inc. | 19.05 | -2.56% | $964.87M | vs LTGO |
Indexes, lists and sector
Latigo Biotherapeutics stock FAQ
What is Latigo Biotherapeutics's stock price today?
LTGO last traded at $13.00 as of Nov 20, 4:00 PM EST, down 1.81% on the day. Prices are delayed at least 15 minutes.
When is Latigo Biotherapeutics's next earnings date?
Latigo Biotherapeutics is expected to report earnings on Thursday, December 3, 2026.
Who is Latigo Biotherapeutics's CEO?
Mr. Todd N. Smith is the chief executive officer of Latigo Biotherapeutics Inc., which has about 66 employees.
What is the LTGO 52-week high?
The 52-week high for LTGO is $25.93 and the 52-week low is $10.24. The stock is currently 49.9% below its high.